Přehled o publikaci

Bacterial viruses (bacteriophages) have significant impact on the evolution of bacteria and regulation of bacterial populations, including the microflora of the human body. Due to the global antibiotic crisis, interest in the use of bacterial viruses, phage-derived enzybiotics and chemical compopunds inspired by structures and functions of phage proteins to combat bacterial infections has increased worldwide. Historical clinical data on the effective use of bacteriophages in patients exists from Eastern Europe, but no evidence of it has been validated under recent European Regulatory standards. Discussions in professional societies such as ESCMID Study Group for Non-traditional Antibacterial Therapy –ESGNTA are currently underway on setting the rules for production and safety of the use of bacteriophage preparations. The regulatory authorities also communicate an increased interest in the therapeutic use of bacteriophages. In July 2021, the European Pharmacopoeia Commission launched work on new general chapter on phage therapy active substances and medicinal products for human and veterinary use, establishing harmonised quality standards for phage therapy products and providing a framework for their safe use in European countries.